Thanks for reposting that, sometimes the phramacist will admit more than doctors. Most of the time they look at you like they are thinking do you know what you just asked for!

The other names for IUDs are on wiki something like nova T, flexi T, copper T, and i read about one that they sew in that is used in china.

berg bow, Hall-Stone ring, Lippes loop, Margulies coil-Gynekoil, Ota ring, and Zipper ring). (antigon, comet, KS wing, Majzlin spring, Saf-T-Coil, Soonawala IUD, Szontagh IUD, and Yusei ring).

In the U.S., the ParaGard T 380A was approved by the FDA in 1984 and became available for use in 1988. It is still the only copper IUD approved for use in the U.S., and was used by 1.3% of women of reproductive age in a 2002 U.S. survey.[47] A wider variety of IUDs are available outside of the U.S. As of 2008[update] in the U.K., for example, ten brands are available: Flexi-T 300, Flexi-T +380, Load 375, Multi-Load Cu 375, Nova T 380, T-Safe Cu 380A, TT 380 Slimline, UT 380 Short, UT 380 Standard, and GyneFix - also called FlexiGard 330 or CuFix PP330.
http://en.wikipedia.org/wiki/Intrauterine_device

Increased menstrual bleeding, often with pain, is the most common problem of IUD use and the most common medical reason for removing IUDs. In clinical trials about 4% to 15% of women stop using IUDs for this reason within a year after insertion. Percentages are usually higher for the Lippes Loops and other unmedicated devices than for copper IUDs.
Older women and women with children generally have lower rates of removal due to bleeding and pain (332, 463). The kind of counseling and support women receive and their attitudes toward using IUDs also influence rates of discontinuation due to bleeding and pain (27). Women who want no more children, for example, may be more tolerant of heavy bleeding and less likely to discontinue than younger women who plan to have more children. Unmedicated and copper IUDs increase the volume of menstrual bleeding per cycle, probably because the IUD disturbs the blood vessels or alters the normal blood clotting mechanism in the lining of the uterus (341, 437). With unmedicated devices, blood flow increases on average by 50% to 100% above preinsertion levels (10, 132, 135, 167, 437); with copper IUDs, 20% to 50% (115, 135, 167, 207, 212, 229).

Unlike other IUDs, hormone-releasing devices decrease menstrual blood flow or, in the case of the LNG-20, may even stop menstruation altogether (amenorrhea)—an effect of the progestin hormone that they release (131, 222, 258, 308, 465, 517, 549, 562, 630). In fact, the LNG-20 has been used successfully to treat women with menorrhagia, or excessive menstrual flow (479). Hormone-releasing IUDs may increase the number of days of light bleeding and spotting. Largely because of removals due to amenorrhea, rates of removal for bleeding or pain for the LNG IUD in developing-country clinical trials were higher than for copper IUDs (517, 549). In contrast, in a European study discontinuation for bleeding and pain was less common with the LNG-20 than with the Nova-T (573) (see Table 1). With good counseling, many women recognize the benefits of decreased menstrual flow, and continuation rates are high (530). With all IUDs, abnormal bleeding and pain may be due not to the IUD itself but to pelvic inflammatory disease (PID), ectopic pregnancy, malignancy, or other conditions (45, 154). Therefore the health care provider should consider whether there is reason to suspect other conditions that might cause bleeding and pain.

Risk of anemia. An estimated 45% of nonpregnant women in developing countries are anemic by WHO's definition (460). Many more have marginal iron levels (10). Thus increased bleeding with copper and unmedicated IUDs could be a cause for concern.

IUD use has not been proved to induce clinical anemia, however. Some 1- and 2-year studies of copper and unmedicated IUDs show significant declines in levels of serum ferritin, which decrease in the early stages of iron depletion, and/or in hemoglobin, which show only in later stages (10, 115, 117, 134, 147, 167, 188, 378, 481). Others find no changes (212, 271, 284, 298, 320, 615). The few long-term studies done have found little increase in the prevalence of anemia (378, 437). In a study of the TCu-380Ag carried out in several developing countries and the US, the proportion of women with anemia rose only from 24% to 25.4% during four years of use (329). Among these women, hemoglobin levels dropped slightly during the first two years of use but then rose even higher than they had been when the women first began using the IUD (549). In a case-control study in the Dominican Republic that involved a population with a high incidence of anemia, women who had used the TCu-380Ag for three or four years were no more likely to have low serum ferritin or hematocrit than women who were not using IUDs (509). In the US and Finland studies report lower serum ferritin levels in long-term IUD users than in nonusers, but no cases of clinical anemia were seen (250, 378). Recent research suggests that women may tolerate much lower serum ferritin levels without developing clinical anemia than had been thought and that intestinal absorption of iron may increase to compensate for heavier menstrual bleeding (615). Also, in developing countries protection against repeated pregnancies—a major cause of iron depletion and anemia—may offset the increased menstrual bleeding caused by IUDs (437).

Hormone-releasing IUDs, by reducing menstrual bleeding and sometimes stopping it completely, may actually protect against anemia (479, 531, 588). The Dominican Republic study found that women who used the LNG-20 for more than three years were significantly less likely to have low serum ferritin or hematocrit than either women not using IUDs or women using unmedicated or copper IUDs (509).

http://www.infoforhealth.org/pr/b6/b6chap2_5.shtml#top

http://www.infoforhealth.org/pr/b6/b6used.shtml

you can see them if you click the link

TCu-380A and TCu-380 Slimline (TCu-380S)

Description: Polyethylene with barium sulfate added for visibility on x-rays. 314 mm2 copper wire on vertical stem; two 33 mm2 solid copper sleeves on each transverse arm. On the 380S the copper sleeves are placed at the ends of the arms and recessed into the plastic.
Developers: Population Council (US) and Ortho Canada (TCu-380S).

Date first marketed: 1982 (TCu-380A).

Major distributors: TCu-380A—FEI Products, US; P.T. Kimia Farma, Indonesia; Produtos Medicos Ltda., Brazil; Ortho-McNeil, US (brand name ParaGard); Schering AG, Commonwealth of Independent States (CIS) (formerly USSR); TCu-380A and TCu-380S (brand name Gyne T Slimline)—Janssen-Ortho Canada; TCu-380S—Janssen-Cilag, Russia; Cilag, France.

Length: 36 mm. Width: 32 mm.

Strings: Two white (formerly blue).

Inserter type and diameter: Withdrawal; 4.4 mm. (Both use the same inserter tube. TCu-380S arms fit completely in tube. With TCu-380A only the tips of the arms fit inside tube.)

Lifespan demonstrated in clinical trials: 10 years.

Approved lifespan: TCu-380A—US, 10 years; CIS, 6 years. TCu-380S—Canada, 2-1/2 years; Europe, various.

Areas of major use: TCu-380A—worldwide; TCu-380S—Canada, Western Europe, Hong Kong.


TCu-200 and TCu-200B

Description: Polyethylene with barium sulfate added for visibility on x-rays. 200 mm2 copper wire wrapped around stem. The TCu-200B (shown) has a ball at the tip of the stem; the TCu-200 does not.

Developers: Howard Tatum (US) and Jaime Zipper (Chile).

Date first marketed: 1972.

Major distributors: TCu-200B—Produtos Medicos Ltda., Brazil; TCu-200—Janssen-Ortho Canada.

Length: 36 mm. Width: 32 mm.

Strings: Two; color varies.

Inserter type and diameter: Withdrawal; 4.4 mm.

Lifespan demonstrated in clinical trials: 6 years.

Approved lifespan: US, 4 years; various European countries, 3 years; Canada, 2 years.

Areas of major use: Bangladesh, India.


Nova T and CuNovaT

Description: Polyethylene with barium sulfate added for visibility on x-rays. Nova T (shown) has 200 mm2 copper wire with a silver core wrapped around the stem. CuNovaT has 380 mm2 wire wrapped around the stem.

Developers: Leiras Oy, Finland.

Date first marketed: Nova T—1979; CuNovaT—1994.

Major distributors: Nova T—Leiras Oy in Scandinavian countries; Schering AG in other countries worldwide; also Pharmacia (Novagard) in UK. CuNovaT—Leiras Oy.

Length: 32 mm. Width: 32 mm.

Strings: Two brown.

Inserter type and diameter: Withdrawal; 3.6 mm.

Approved lifespan: Nova T and CuNovaT—5 years in various European countries.

Lifespan demonstrated in clinical trials: Nova T—5 years; CuNovaT—3 years to date.

Areas of major use: Nova T—Europe, Canada, Asia and Pacific; CuNovaT—Denmark, Finland, Norway, Sweden.


Lippes Loop

Description: Polyethylene with barium sulfate added for visibility on x-rays. Available in four sizes, designated A (left) through D (right).

Developer: Jack Lippes (US).

Date first marketed: 1962.

Major distributor: P.T. Kimia Farma, Indonesia (in-country distribution only).

Length: A—26.2 mm; B—25.2 mm; C—27.5 mm; D—27.5 mm.

Width: A—22.2 mm; B—27.4 mm; C—30.0 mm; D—30.0 mm.

Strings: Two; A—blue, B—black, C—yellow, D—white.

Inserter type and diameter: Push-out; 4.7 mm.

Areas of major use: Formerly, worldwide except China; currently, Indonesia.


Multiload-250 (MLCu-250) and 375 (MLCu-375)

Description: Polyethylene with two flexible arms with spurs. The MLCu-250 has 250 mm2 copper wire on the stem and is available in 2 sizes, Standard (top left) and Short (top right). The MLCu-375 has 375 mm2 copper wire and is available in 2 sizes, Standard (bottom left) and SL (bottom right).

Developer: W.A.A. van Os (Netherlands).

Date first marketed: 1974.

Distributors: Produced by Multilan AG, Switzerland, in Ireland and by Nanjing Organon Pharmaceutical Products, China. Distributed through subsidiaries of NV Organon, the Netherlands, member of AKZO-NOBEL Pharma Division; Laboratoires CCD, France. Also manufactured for in-country use in Indonesia.

Length: Standard (250 and 375)—35 mm; 375SL—29 mm; 250 Short—24 mm.

Width: All types—18 mm.

Strings: Two blue or colorless.

Inserter type: Withdrawal (no plunger).

Insertion diameter: All types—12 mm (arms remain outside inserter tube).

Lifespan demonstrated in clinical trials: MLCu-375--5 years.

Approved lifespan: MLCu-250—3 years; MLCu-375—5 years.

Areas of major use: Europe (including Russia and other members of the Commonwealth of Independent States), Australia, India, Vietnam and other Southeast Asian countries, New Zealand, Latin America.


TCu-220C

Description: Polyethylene with barium sulfate added for visibility on x-rays. 220 mm2 copper in 7 copper sleeves—2 on the arms and 5 on the stem.

Developer: Population Council (US).

Date first marketed: 1980.

Major distributors: Laboratorios Alpha, Mexico; Tianjin Medical Instrument Corporation, Factory No. 4, China (in-country distribution only).

Length: 36 mm. Width: 32 mm.

Strings: Two.

Inserter type and diameter: Withdrawal; 4.4 mm.

Lifespan demonstrated in clinical trials: 10 years.

Approved lifespan: Mexico, 3 years.

Areas of major use: China, Mexico


Progestasert Intrauterine Progesterone Contraceptive System

Description: Ethylene vinyl acetate copolymer. Vertical stem contains a reservoir of 38 mg progesterone and barium sulfate (for visibility on x-rays) in silicone oil base. Releases 65 micrograms progesterone per 24 hours.

Developer: Alza Corporation (US).

Date first marketed: 1976.

Distributors: Alza Corporation, US; Theraplix Divison, Rhone-Poulenc Rorer, France.

Length: 36 mm. Width: 32 mm.

Strings: Two blue-black.

Inserter type and diameter: Withdrawal; 8 mm.

Approved lifespan: US, one year; France, 18 months.

Areas of major use: US, France.


Levonorgestrel (LNG-20) Intrauterine System (Mirena/Levonova)

Description: Polyethylene T frame surrounded by a levonorgestrel-containing cylinder. The cylinder is covered with a rate-controlling membrane. The release rate is 20 micrograms levonorgestrel per 24 hours.

Developers: Leiras Oy with the Population Council.

Date first marketed: 1990 in Finland.

Major distributors: Leiras Oy in Scandinavian countries and Asia-Pacific, Pharmacia-Leiras in selected European countries.

Length: 32 mm. Width: 32 mm.

Hormone cylinder: length 19 mm, outer diameter 2.8 mm, inner diameter 1.2 mm.

Strings: Two brown.

Inserter type and diameter: Withdrawal; 4.75 mm.

Lifespan demonstrated in clinical trials: 5 years.

Approved lifespan: UK, 3 years; other countries, 5 years.

Areas of major use: Denmark, Finland, Norway, Sweden. Launched in UK and Singapore in 1995. Also approved for use in Belgium, France, Iceland, and Switzerland.